Zion Market Research Global Immunotherapy Drugs Market, 2016–2024 | Page 3

Immunotherapy Drugs Market
revenue in the coming years. Materialization of biosimilars is another driving factor for the
immunotherapy drugs market.
Global Immunotherapy Drugs Market: Segmentation
The immunotherapy drugs market is classified into therapy area, type of drug, and region.
The therapy area is divided into infectious diseases, cancer, autoimmune & inflammatory
diseases, and others. The cancer segment is further sub-segmented into the malignant and
solid tumor. Depending on the type of drug, the market is fragmented into checkpoint
inhibitors, checkpoint inhibitors, monoclonal antibodies, interleukins, adult vaccines,
interferons alpha & beta, and others. The adult vaccine is sub-segmented into therapeutic
vaccines and preventive vaccines. Region-wise, the market is diversified into North
America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Request Report TOC (Table of Contents) @
https://www.zionmarketresearch.com/toc/immunotherapy-drugs-market
Global Immunotherapy Drugs Market: Regional Analysis
North America is expected to contribute the largest market share, whereas Asia-Pacific will
be the fastest-growing region for immunotherapy drugs. Favorable government initiatives,
availability of technologically advanced health care research framework, personalized
medicine, healthy R&D investment, and development of next generation sequencing are
some of the key factors responsible for the growth of immunotherapy drugs in North
America. Low cost of manufacturing coupled with an acceptable regulatory scenario in this
region may give rise to the market growth. Prosperous middle class willing to spend on
quality healthcare products along with the presence of a vast pool of geriatric population in